drugset
drugset / Trial / NCT00264875

Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy

NCT00264875 ↗

Phase 3 Completed 220 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of pregabalin in reducing neuropathic pain associated with HIV neuropathy

Timeline

Start
2006-02
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 300 mg —

Indications

HIV infectious disease peripheral neuropathy